Company intelligence / Profile preview

Bugworks Research Inc.

Ownership: Private
Employees: ~50
Development stage: Phase 1

Overview

Lead antibacterial candidate BWC0977 is currently in Phase 1 clinical trials in Australia. It has demonstrated in vitro activity against WHO critical priority pathogens, including carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae. The company also has a lead anticancer candidate ready for IND submission.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

14 assets

BWC0977

13 more assets in the full pipeline.

Request access →

Partnerships

GARDP (Global Antibiotic Research & Development Partnership)CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator)

Beyond the preview

Go deeper on Bugworks Research Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bugworks Research Inc..

Explore the full profile